The Link Between the Microbiota and HER2+ Breast Cancer: The New Challenge of Precision Medicine

Modica, Martina Di; Arlotta, Valeria; Sfondrini, Lucia; Tagliabue, Elda; Triulzi, Tiziana

doi:10.3389/fonc.2022.947188

Cited by 10 publications

(14 citation statements)

References 129 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been shown that the constitution of the microbiota influences tumour biology, such as oncogenic signalling, drug metabolism, or immune system regulation. All these aspects will contribute to the cancer development, growth, and treatment response [16].…”

Section: Introductionmentioning

confidence: 99%

Breast Cancer Survivors and Healthy Women: Could Gut Microbiota Make a Difference?—“BiotaCancerSurvivors”: A Case-Control Study

Caleça

Ribeiro²,

Vitorino

et al. 2023

Cancers

View full text Add to dashboard Cite

In this first analysis, samples from 23 BC survivors (group 1) and 291 healthy female controls (group 2) were characterised through the V3 and V4 regions that encode the “16S rRNA” gene of each bacteria. The samples were sequenced by next-generation sequencing (NGS), and the taxonomy was identified by resorting to Kraken2 and improved with Bracken, using a curated database called ‘GutHealth_DB’. The α and β-diversity analyses were used to determine the richness and evenness of the gut microbiota. A non-parametric Mann-Whitney U test was applied to assess differential abundance between both groups. The Firmicutes/Bacteroidetes (F/B) ratio was calculated using a Kruskal-Wallis chi-squared test. The α-diversity was significantly higher in group 1 (p = 0.28 × 10−12 for the Chao index and p = 1.64 × 10−12 for the ACE index). The Shannon index, a marker of richness and evenness, was not statistically different between the two groups (p = 0.72). The microbiota composition was different between the two groups: a null hypothesis was rejected for PERMANOVA (p = 9.99 × 10−5) and Anosim (p = 0.04) and was not rejected for β-dispersion (p = 0.158), using Unifrac weighted distance. The relative abundance of 14 phyla, 29 classes, 25 orders, 64 families, 116 genera, and 74 species differed significantly between both groups. The F/B ratio was significantly lower in group 1 than in group 2, p < 0.001. Our study allowed us to observe significant taxonomic disparities in the two groups by testing the differences between BC survivors and healthy controls. Additional studies are needed to clarify the involved mechanisms and explore the relationship between microbiota and BC survivorship.

show abstract

Section: Introductionmentioning

confidence: 99%

Breast Cancer Survivors and Healthy Women: Could Gut Microbiota Make a Difference?—“BiotaCancerSurvivors”: A Case-Control Study

Caleça

Ribeiro²,

Vitorino

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Trastuzumab, a HER2 targeted therapy, prevents HER2 receptor dimerization and activates the innate immune response 47 . However, differences in gut microbiota brought about by usage of antibiotics impact the activation of the innate immune response, thus affecting the efficacy of trastuzumab therapy 27,48 . Studies have thus demonstrated the active role of microbiota in trastuzumab response, and modulation of this microbiome may facilitate better treatment response.…”

Section: Microbiome and Breast Cancermentioning

confidence: 99%

Exploring the human microbiome – A step forward for precision medicine in breast cancer

Jotshi,

Sukla,

Haque

et al. 2023

Cancer Reports

View full text Add to dashboard Cite

BackgroundThe second most frequent cancer in the world and the most common malignancy in women is breast cancer. Breast cancer is a significant health concern in India with a high mortality‐to‐incidence ratio and presentation at a younger age.Recent FindingsRecent studies have identified gut microbiota as a significant factor that can have an influence on the development, treatment, and prognosis of breast cancer. This review article aims to describe the influence of microbial dysbiosis on breast cancer occurrence and the possible interactions between oncobiome and specific breast cancer molecular subtypes. The review further also discusses the role of epigenetics and diet/nutrition in the regulation of the gut and breast microbiome and its association with breast cancer prevention, therapy, and recurrence. Additionally, the recent technological advances in microbiome research, including next‐generation sequencing (NGS) technologies, genome sequencing, single‐cell sequencing, and microbial metabolomics along with recent advances in artificial intelligence (AI) have also been reviewed. This is an attempt to present a comprehensive status of the microbiome as a key cancer biomarker.ConclusionWe believe that correlating microbiome and carcinogenesis is important as it can provide insights into the mechanisms by which microbial dysbiosis can influence cancer development and progression, leading to the potential use of the microbiome as a tool for prognostication and personalized therapy.

show abstract

“…Прогноз раннего РМЖ зависит от параметров клеточной автономии и иммунитета. Влияние кишечного микробиома на клинический исход раннего РМЖ был впервые оценен S. [6].…”

Section: связь с клинико-морфологическими параметрами лечением и исхо...unclassified

“…Количество исследований, посвященных различиям между микробиотой кишечника больных РМЖ и здоровых женщин, значительно увеличивается [3][4][5][6]. Среди симбиотических микробных популяций человека наиболее тщательно изучены и охарактеризованы бактерии, обитающие в кишечнике.…”

Section: Introductionunclassified

Microbiome, immune system and cancer: three sides of the one medal

et al. 2023

View full text Add to dashboard Cite

Purpose of the study to analyze current ideas about the relationship between the microbiota (microbiome) and the human body in the aspect of cancer pathogenesis, ambivalent character of these interactions, and the role of the immune system and immunoinfammatory status that promotes carcinogenesis or prevents neoplastic processes.Material and Methods. Literature search was carried out using Medline, Cochrane Library, Elibrary and PubMed systems, including publications over the last 7 years.Results. The microbiota includes all communities of commensal, symbiotic, and pathogenic microorganisms: bacteria, fungi, archaea, and viruses that colonize the gastrointestinal tract and other organs and tissues. The microbiome is an important factor in cancer pathogenesis due to its involvement in the basic physiological functions of the host, such as digestion, development of the immune system, and modulation of endocrine functions. In the review, the influence of microbiota of different locations (gastrointestinal tract, breast, intravaginal tract) on the development and progression of breast, colorectal and cervical cancers was discussed. The role of the microbiome in cancer pathogenesis is realized by the participation in neoplastic transformation of the epithelium, regulation of tumor progression under conditions of manifested malignant process, and modifcation of the therapeutic effect of standard drugs, including the development of original probiotic-based anticancer agents. The study of the mechanisms of action of the microbiome in the host organism opens up prospects for the development of new approaches to cancer therapy. Particular attention was paid to the mechanisms of the immunomodulatory effect of the microbiota in terms of reducing the risk of malignancy, regulating tumor progression and participating in antitumor therapy. The clinical significance of determining pathogenetically significant microbial markers associated with the aggressive form of cancer, response to treatment and toxicity of therapy was discussed. Particular attention should be paid to the potential mechanisms of interaction between cancer – microbiome – probiotics, since the latter can provide modification of malignancy processes, exert an antitumor effect, and modulate the effectiveness of drug therapy. The feasibility of editing the microbiota by probiotics was considered, and antitumor properties (effects) of bacteria and strategies for modifying the microbiome for the prevention and treatment of cancer were discussed.

show abstract

The Link Between the Microbiota and HER2+ Breast Cancer: The New Challenge of Precision Medicine

Cited by 10 publications

References 129 publications

Breast Cancer Survivors and Healthy Women: Could Gut Microbiota Make a Difference?—“BiotaCancerSurvivors”: A Case-Control Study

Breast Cancer Survivors and Healthy Women: Could Gut Microbiota Make a Difference?—“BiotaCancerSurvivors”: A Case-Control Study

Exploring the human microbiome – A step forward for precision medicine in breast cancer

Microbiome, immune system and cancer: three sides of the one medal

Contact Info

Product

Resources

About